The firm said it has received positive feedback from the FDA on the design of a Phase III trial of ELI-002 in KRAS-mutant pancreatic cancer.

The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...

Received supportive FDA feedback on key elements of the potential ELI-002 Phase 3 study design, including dose, schedule, ...

Additionally, Circio is actively developing a cancer vaccine, TG01, targeting KRAS mutations, with ongoing clinical trials in the USA and Norway. For further insights into GB:0RIS stock ...

with KRAS G12C mutations, as “comprehensive data for this medicine [was] not yet available.” Mirati – which already has FDA approval for Krazati for this indication – said it disagrees ...

It’s the most frequently mutated oncogene in cancer. About 30% of patients with lung adenocarcinoma harbor KRAS mutations, which also drive pancreatic, colorectal and other cancers. Nabet’s team ...

The combination treatment specifically targets KRAS-mutated metastatic colorectal cancer (CRC) to improve progression-free survival. The approval was based on results from CodeBreaK 300 ...

The phase 3 RAMP 301 trial aims to confirm efficacy and potentially expand the treatment's indication beyond KRAS mutation status. Low-grade serous ovarian cancer is highly recurrent, less sensitive ...